Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2001-04-02
2003-02-18
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C435S325000, C435S326000, C530S387100, C530S389600, C530S388100, C530S388230, C530S388240, C530S389100, C530S389200
Reexamination Certificate
active
06521228
ABSTRACT:
BACKGROUND OF THE INVENTION
The programmed cell death known as apoptosis is distinct from cell death due to necrosis. Apoptosis occurs in embryogenesis, metamorphosis, endocrine-dependent tissue atrophy, normal tissue turnover, and death of immune thymocytes (induced through their antigen-receptor complex or by glucocorticoids) (Itoh et al.,
Cell
66:233, 1991). During maturation of T-cells in the thymus, T-cells that recognize self-antigens are destroyed through the apoptotic process, whereas others are positively selected. The possibility that some T-cells recognizing certain self epitopes (e.g., inefficiently processed and presented antigenic determinants of a given self protein) escape this elimination process and subsequently play a role in autoimmune diseases has been suggested (Gammon et al.,
Immunology Today
12:193, 1991).
A cell surface antigen known as Fas has been reported to mediate apoptosis and is believed to play a role in clonal deletion of self-reactive T-cells (Itoh et al.,
Cell
66:233, 1991; Watanabe-Fukunage et al.,
Nature
356:314, 1992). Cross-linking a specific monoclonal antibody to Fas has been reported to induce various cell lines to undergo apoptosis (Yonehara et al.,
J. Exp. Med.,
169:1747, 1989; Trauth et al.,
Science,
245:301, 1989). However, under certain conditions, binding of a specific monoclonal antibody to Fas can have a costimulatory effect on freshly isolated T cells (Alderson et al.,
J. Exp. Med.
178:2231, 1993).
DNAs encoding a rat Fas ligand (Suda et al.,
Cell,
75:1169, 1993) and a human Fas ligand (Takahashi et al.,
International Immunology
6:1567, 1994) have been isolated. Binding of the Fas ligand to cells expressing Fas antigen has been demonstrated to induce apoptosis (Suda et al., supra, and Takahashi et al., supra).
Investigation into the existence and identity of other molecule(s) that play a role in apoptosis is desirable. Identifying such molecules would provide an additional means of regulating apoptosis, as well as providing further insight into the development of self-tolerance by the immune system and the etiology of autoimmune diseases.
SUMMARY OF THE INVENTION
The present invention provides a novel cytokine protein, as well as isolated DNA encoding the cytokine and expression vectors comprising the isolated DNA. Properties of the novel cytokine, which is a member of the tumor necrosis factor (TNF) family of ligands, include the ability to induce apoptosis of certain types of target cells. This protein thus is designated TNF Related Apoptosis Inducing Ligand (TRAIL). Among the types of cells that are killed by contact with TRAIL are cancer cells such as leukemia, lymphoma, and melanoma cells, and cells infected with a virus.
A method for producing TRAIL polypeptides involves culturing host cells transformed with a recombinant expression vector that contains TRAIL-encoding DNA under conditions appropriate for expression of TRAIL, then recovering the expressed TRAIL polypeptide from the culture. Antibodies directed against TRAIL polypeptides are also provided.
REFERENCES:
patent: 5512435 (1996-04-01), Renschler et al.
patent: 5716805 (1998-02-01), Srinivasan et al.
patent: 5876954 (1999-03-01), Perron et al.
patent: 6030945 (2000-02-01), Ashkenazi
patent: 6046048 (2000-04-01), Ashkenazi et al.
patent: WO 97/25428 (1997-07-01), None
patent: WO 97/33899 (1997-09-01), None
patent: WO 97/46686 (1997-12-01), None
patent: WO 99/07408 (1999-02-01), None
patent: WO 99/36535 (1999-07-01), None
patent: WO 99/48527 (1999-09-01), None
patent: WO 00/63253 (2000-10-01), None
Banner et al., “Crystal structure of the soluble human 55 kd TNF receptor-human TNF&bgr; complex: implications for TNF receptor activation,”Cell 73: 431-445, 1993.
Bell, G.I. and Takeda, J., NCBI databank record, accession No. T10524, Jul. 28, 1993.
Belliveau et al., “Presence of the cytokine APO-2L (TRAIL), in the cerebrospinal fluid of multiple sclerosis patients,” Society for Neuroscience Abstracts 23(1-2). 1997; p. 2207.
Belliveau et al., “Presence of the cytokine, APO-2L (TRAIL), in the cerebrospinal fluid of multiple sclerosis patients,” Poster presented at the 27thAnnual Meeting of the Society for Neuroscience, Oct. 25-30, 1997, New Orleans.
Beutler and van Huffel, “Unraveling function in the TNF ligand and receptor families,”Science 264: 667-668, 1994.
Bowie, et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions,”Science 247: 1306-1310, 1990.
Genexpress, NCBI databank record, accession No. Z36726, Aug. 18, 1994.
Goodwin et al., “Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor,”Eur. J. Immunol. 23: 2631-2641, 1993.
Goodwin et al., “Study of the structure and function of Trail, a new member of the TNF ligand family,”Eur. Cytokine Network 7(2): 166, 1996.
Gruss, H.-J. and Dower, S.K., “Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas,”Blood 85(12): 3378-3404, 1995.
Hillier et al., NCBI databank record, accession No. T90422, Mar. 20, 1995.
Hillier et al., NCBI databank record, accession No. T82085, Mar. 10, 1995.
Hillier et al., NCBI databank record, accession No. R31020, Apr. 28, 1995.
Hollenbaugh et al., “Construction of immunoglobulin fusion proteins,”Current Protocols in Immunology, Supp. 4, 1992, 10.19.1-10.19.11.
Hoppe et al., “A parallel three standard &agr;-helical bundle at the nucleation site of collagen triple-helix formation,”FEBS Letters 344: 191-195, 1994.
Jo, M. et al., “Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand,”Nature Medicine 6: 564-567, May 2000.
Kroemer, “The pharmacology of T cell apoptosis,”Adv. Immunol. 58: 211-296, 1995.
Landschultz, et al., “The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins,”Science 240: 1759-1764, 1988.
Marsters et al., “Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA,”Current Biology 6(6): 750, 1996.
Menard et al., “A gliotoxic factor and multiple sclerosis,”J Neurological Sciences 154: 209-221, 1998.
Mikayama, T. et al., “Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor,”Proc. Natl. Acad. Sci. USA 90:10056-10060, 1993.
O'Mahoney et al., “An immune suppressive factor derived from esophageal squamous carcinoma induces apoptosis in normal and transformed cells of lymphoid lineage,”J. Immunol. 151(9): 4847-4856, 1993.
Pitti et al., “Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family,”J. Biol. Chem. 271(22): 12687-12690, 1996.
Reiger, F. and J. Belliveau, report on research studies, in letter dated Aug. 31, 1999.
Rieger, R. et al., Glossary of Genetics and Cytogenetics, Fourth Ed., Springer-Verlag, pp. 16-19, 1976.
Sachs and Lotem, “Control of programmed cell death in normal and leukemic cells: new implications for therapy,”Blood 82(1): 15-21, 1993.
Smith et al., “The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death,”Cell 76: 959-962, 1994.
Smith et al., “CD30 Antigen, a marker for Hodgkin's Lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF,”Cell 73: 1349-1360, 1993.
Smith et al., “Trail: a new member of the TNF ligand family that induces apoptosis,”Eur. Cytokine Network 7(3): 429, 1996.
Suda et al., “Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family,”Cell 75: 1169-1178, 1993.
Takahashi et al., “Human Fas ligand: gene structure, chromosomal location and species specificity,”International Immunol. 6(10): 1567-1574, 1994.
Takeda et al., “A molecular inventory of human pancreatic islets: sequence analysis of 1000 cDNA clones,”Human Molecular Genetics 2(11): 1793-1798, 1993.
Voet et al., Biochemistry, John Wiley & Sons, Inc., pp. 126-128 and 228-234, 1990.
Wiley et al., “Identification and characterization of a new member of the TNF family that i
Goodwin Raymond G.
Wiley Steven R.
Anderson Kathryn A.
Immunex Corporation
Mertz Prema
LandOfFree
Antibodies directed against trail does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies directed against trail, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies directed against trail will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3176394